Posaconazole: SCH 56592.
Posaconazole [SCH 56592, SPRIAFIL, Noxafil] is an orally active triazole derivative that is in phase III trials with the Schering-Plough Research Institute (SPRI) in the US for the treatment of serious opportunistic fungal infections, including aspergillosis, candidiasis, coccidioidomycosis and fusariosis. This profile has been selected from R&D Insight, a pharmaceutical intelligence database produced by Adis International Ltd. Preclinical studies have also been conducted in Italy for the potential treatment of Cryptococcus neoformans infection (cryptococcosis).
D000284:Administration, Oral; D000935:Antifungal Agents / Q000009:adverse effects / Q000493:pharmacokinetics / Q000627:therapeutic use*; D002986:Clinical Trials as Topic; D065607:Cytochrome P-450 Enzyme Inhibitors; D006801:Humans; D009181:Mycoses / Q000188:drug therapy* / Q000201:enzymology; D009894:Opportunistic Infections / Q000188:drug therapy* / Q000201:enzymology; D010088:Oxidoreductases / Q000037:antagonists & inhibitors; D058886:Sterol 14-Demethylase; D016896:Treatment Outcome; D014230:Triazoles / Q000009:adverse effects / Q000493:pharmacokinetics / Q000627:therapeutic use*
D000935:Antifungal Agents; C548418:CYP51A1 protein, human; D065607:Cytochrome P-450 Enzyme Inhibitors; D014230:Triazoles; C101425:posaconazole; D010088:Oxidoreductases; D058886:Sterol 14-Demethylase